PSORS4
MCID: PSR025
MIFTS: 33

Psoriasis 4 (PSORS4)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 4

MalaCards integrated aliases for Psoriasis 4:

Name: Psoriasis 4 56 12 15
Psoriasis Susceptibility 4 56 13
Psors4 56 12
Psoriasis 4, Susceptibility to 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0111280
OMIM 56 603935
OMIM Phenotypic Series 56 PS177900

Summaries for Psoriasis 4

Disease Ontology : 12 A psoriasis that has material basis in variation in a region on chromosome 1q21.

MalaCards based summary : Psoriasis 4, also known as psoriasis susceptibility 4, is related to psoriasis 2 and psoriasis. An important gene associated with Psoriasis 4 is PSORS4 (Psoriasis Susceptibility 4), and among its related pathways/superpathways are Developmental Biology and Defensins. The drugs Indirubin and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include skin and endothelial.

More information from OMIM: 603935 PS177900

Related Diseases for Psoriasis 4

Graphical network of the top 20 diseases related to Psoriasis 4:



Diseases related to Psoriasis 4

Symptoms & Phenotypes for Psoriasis 4

Clinical features from OMIM:

603935

Drugs & Therapeutics for Psoriasis 4

Drugs for Psoriasis 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Indirubin Investigational Phase 2 479-41-4
2 Immunoglobulins Phase 2
3 Antibodies Phase 2
4 Antibodies, Monoclonal Phase 2
5
Methotrexate Approved Early Phase 1 59-05-2, 1959-05-2 126941
6
leucovorin Approved Early Phase 1 58-05-9 6006 143
7
Dexamethasone acetate Approved, Investigational, Vet_approved Early Phase 1 1177-87-3
8
Dexamethasone Approved, Investigational, Vet_approved Early Phase 1 50-02-2 5743
9
Folic acid Approved, Nutraceutical, Vet_approved Early Phase 1 59-30-3 6037
10 Vitamin B Complex Early Phase 1
11 Folic Acid Antagonists Early Phase 1
12 Folate Early Phase 1
13 Antimetabolites Early Phase 1
14 Vitamin B9 Early Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis Treated by Narrow Band UVB Therapy Withdrawn NCT01121081 Phase 3 Alga Dunaliella Bardawil;Placebo
2 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis Completed NCT00192517 Phase 2 MEDI-522
3 Mechanistic Study of Indigo Naturalis in Treating Psoriasis: Local or Systemic Manipulation of Inflammation and Induction of Immunoregulation Completed NCT02088281 Phase 2 Indigo naturalis extract in oil ointment
4 Study of Topical Application of AS101 for the Treatment of Psoriasis Withdrawn NCT00788424 Phase 2 AS101 Cream
5 Cyclosporine in the Pharmacotherapy of Psoriasis Withdrawn NCT00377325 Phase 2 Cyclosporine
6 Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study Unknown status NCT02644044 Early Phase 1 Intrathecal methotrexate

Search NIH Clinical Center for Psoriasis 4

Genetic Tests for Psoriasis 4

Anatomical Context for Psoriasis 4

MalaCards organs/tissues related to Psoriasis 4:

40
Skin, Endothelial

Publications for Psoriasis 4

Articles related to Psoriasis 4:

(show top 50) (show all 61)
# Title Authors PMID Year
1
Association of skin barrier genes within the PSORS4 locus is enriched in Singaporean Chinese with early-onset psoriasis. 61 56
18787534 2009
2
Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21. 61 56
16362825 2006
3
Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21. 56 61
16912508 2006
4
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. 61 56
16163348 2005
5
Characterization of the loricrin (LOR) gene as a positional candidate for the PSORS4 psoriasis susceptibility locus. 61 56
15598222 2004
6
Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. 56 61
11348461 2001
7
Loss-of-function mutations in filaggrin gene associate with psoriasis vulgaris in Chinese population. 56
22407025 2012
8
FLG mutation p.Lys4021X in the C-terminal imperfect filaggrin repeat in Japanese patients with atopic eczema. 56
19663875 2009
9
Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. 56
19169253 2009
10
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. 56
19169255 2009
11
Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. 56
10577939 1999
12
Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. 56
9886260 1999
13
Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? 61
32367558 2020
14
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. 61
30887876 2020
15
Coexistence of Anogenital Psoriasis and Genital Warts - Is There an Optimal Treatment? 61
31969241 2019
16
Mycosis fungoides with spongiosis: A potential diagnostic pitfall. 61
30989664 2019
17
A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab. 61
30941695 2019
18
Interpretation of Nondiagnostic Vulvar Biopsies. 61
29271860 2018
19
Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes. 61
28667056 2017
20
Health-related Quality of Life in Children and Adolescents with Psoriasis: A Systematic Review and Meta-analysis. 61
27983745 2017
21
NOD-like receptor signaling and inflammasome-related pathways are highlighted in psoriatic epidermis. 61
26976200 2016
22
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis. 61
26556603 2015
23
Opposing Effects of Zac1 and Curcumin on AP-1-Regulated Expressions of S100A7. 61
26633653 2015
24
Analysis of protein-protein interaction between late cornified envelope proteins and corneodesmosin. 61
25078048 2014
25
Inflammatory bowel diseases: Current problems and future tasks. 61
25133045 2014
26
Failure to find evidence for deletion of LCE3C and LCE3B genes at PSORS4 contributing to psoriasis susceptibility in Tunisian families. 61
24485035 2014
27
Associations between the major histocompatibility complex class I chain-related gene A transmembrane (MICA-TM) polymorphism and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. 61
23974432 2014
28
Regulation of late cornified envelope genes relevant to psoriasis risk by plant-derived cyanidin. 61
24393842 2014
29
Control of late cornified envelope genes relevant to psoriasis risk: upregulation by 1,25-dihydroxyvitamin D3 and plant-derived delphinidin. 61
23839497 2013
30
Blaschko-linear manifestations of polygenic inflammatory diseases: analysis of 17 cases. 61
24185002 2013
31
The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. 61
22863575 2013
32
Worldwide population distribution of the common LCE3C-LCE3B deletion associated with psoriasis and other autoimmune disorders. 61
23594316 2013
33
Cumulative life course impairment: identifying patients at risk. 61
23796811 2013
34
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. 61
23205325 2012
35
HLA-C, CSTA and DS12346 susceptibility alleles confer over 100-fold increased risk of developing psoriasis: evidence of gene interaction. 61
21412248 2011
36
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. 61
21332464 2011
37
New psoriasis susceptibility genes: momentum for skin-barrier disruption. 61
21494239 2011
38
Gene from a psoriasis susceptibility locus primes the skin for inflammation. 61
21148126 2010
39
Depression in adult dermatology outpatients. 61
21205547 2010
40
Deletion of LCE3C and LCE3B genes at PSORS4 does not contribute to susceptibility to psoriatic arthritis in German patients. 61
19439430 2010
41
Association of psoriasis to PGLYRP and SPRR genes at PSORS4 locus on 1q shows heterogeneity between Finnish, Swedish and Irish families. 61
18643845 2009
42
Comparison of the Expression Profile of JunB, c-Jun, and S100A8 (Calgranulin A) in Psoriasis Vulgaris and Guttate Psoriasis. 61
20548852 2009
43
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. 61
18369459 2008
44
Etanercept treatment for children and adolescents with plaque psoriasis. 61
18199863 2008
45
[Changes of ultrastructure and p-53 protein expression on the peripheral blood lymphocytes of patients with vulgar form of psoriasis after balneal therapy in resort "nunisi"]. 61
15988091 2005
46
Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. 61
15757824 2005
47
Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis. 61
15517637 2004
48
[Study of the association between HLA-DQA1 alleles and environmental factors in psoriasis]. 61
12667357 2002
49
Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees. 61
12384771 2002
50
Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. 61
12056961 2002

Variations for Psoriasis 4

Expression for Psoriasis 4

Search GEO for disease gene expression data for Psoriasis 4.

Pathways for Psoriasis 4

Pathways related to Psoriasis 4 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 LORICRIN LCE3C LCE3B LCE3A LCE1C HRAS
2
Show member pathways
11.59 S100A7 PGLYRP4 PGLYRP3 PGLYRP1
3
Show member pathways
11.56 LORICRIN LCE3C LCE3B LCE3A LCE1C CDSN

GO Terms for Psoriasis 4

Cellular components related to Psoriasis 4 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornified envelope GO:0001533 8.62 LORICRIN CDSN

Biological processes related to Psoriasis 4 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.92 S100A7 PGLYRP4 PGLYRP3 PGLYRP1 HLA-C
2 keratinization GO:0031424 9.8 LORICRIN LCE3C LCE3B LCE3A LCE1C
3 defense response to Gram-negative bacterium GO:0050829 9.73 S100A7 LCE3C LCE3B LCE3A
4 antimicrobial humoral response GO:0019730 9.69 S100A7 PGLYRP3 PGLYRP1
5 keratinocyte differentiation GO:0030216 9.67 S100A7 LORICRIN CDSN
6 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.67 S100A7 PGLYRP4 PGLYRP3 PGLYRP1
7 epidermis development GO:0008544 9.63 S100A7 LCE3C LCE3B LCE3A LCE1C CDSN
8 negative regulation of interferon-gamma production GO:0032689 9.54 PGLYRP3 PGLYRP1
9 detection of bacterium GO:0016045 9.5 PGLYRP4 PGLYRP3 PGLYRP1
10 growth of symbiont in host GO:0044117 9.48 PGLYRP3 PGLYRP1
11 negative regulation of natural killer cell differentiation involved in immune response GO:0032827 9.46 PGLYRP3 PGLYRP1
12 peptidoglycan catabolic process GO:0009253 9.43 PGLYRP4 PGLYRP3 PGLYRP1
13 defense response to Gram-positive bacterium GO:0050830 9.43 PGLYRP4 PGLYRP3 PGLYRP1 LCE3C LCE3B LCE3A
14 killing of cells of other organism GO:0031640 9.1 PGLYRP4 PGLYRP3 PGLYRP1 LCE3C LCE3B LCE3A

Molecular functions related to Psoriasis 4 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidoglycan binding GO:0042834 9.33 PGLYRP4 PGLYRP3 PGLYRP1
2 peptidoglycan receptor activity GO:0016019 9.13 PGLYRP4 PGLYRP3 PGLYRP1
3 N-acetylmuramoyl-L-alanine amidase activity GO:0008745 8.8 PGLYRP4 PGLYRP3 PGLYRP1

Sources for Psoriasis 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....